|Bid||0.7500 x 334700|
|Ask||0.7700 x 1317400|
|Day's range||0.7500 - 0.7700|
|52-week range||0.7250 - 1.8400|
|Beta (5Y monthly)||1.40|
|PE ratio (TTM)||N/A|
|Earnings date||24 Aug 2022 - 29 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||25 Mar 1988|
|1y target est||N/A|
The big shareholder groups in Starpharma Holdings Limited ( ASX:SPL ) have power over the company. Insiders often own a...
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
In a major development for its VIRALEZE™ antiviral nasal spray, Starpharma (ASX: SPL) today announced that its potent antiviral agent, SPL7013, achieved the maximum possible virucidal effect against the highly transmissible Omicron variant of SARS-CoV-2.